DPYD Antikörper (AA 265-370)

Produktnummer ABIN1387275

Produktdetails anti-DPYD Antikörper

Target: DPYD (Dihydropyrimidine Dehydrogenase (DPYD))

Bindungsspezifität: AA 265-370

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser DPYD Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Homologie: Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse,Rabbit

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human DPYD

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu DPYD

Target: DPYD (Dihydropyrimidine Dehydrogenase (DPYD))

Andere Bezeichnung: Dpyd (DPYD Produkte)

Synonyme: DPYD antikoerper, dpyd antikoerper, zgc:77205 antikoerper, AI315208 antikoerper, DPD antikoerper, E330028L06Rik antikoerper, DHP antikoerper, DHPDHASE antikoerper, dhp antikoerper, dhpdhase antikoerper, dpd antikoerper, 14.t00017 antikoerper, DDBDRAFT_0189681 antikoerper, DDBDRAFT_0231100 antikoerper, DDB_0189681 antikoerper, DDB_0231100 antikoerper, dpyda antikoerper, zgc:153505 antikoerper, dihydropyrimidine dehydrogenase antikoerper, dihydropyrimidine dehydrogenase b antikoerper, dihydropyrimidine dehydrogenase L homeolog antikoerper, dihydropyrimidine dehydrogenase [NADP(+)] antikoerper, dihydropyrimidine dehydrogenase a, tandem duplicate 1 antikoerper, DPYD antikoerper, Dpyd antikoerper, dpydb antikoerper, dpyd.L antikoerper, EHI_012980 antikoerper, LOC5573038 antikoerper, EDI_044620 antikoerper, pyd1 antikoerper, dpyda.1 antikoerper

Hintergrund:

Synonyms: DHP, DHPDHase, Dihydropyrimidine dehydrogenase [NADP+], Dihydropyrimidine dehydrogenase, Dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase, DPD, DPYD, DPYD_HUMAN, MGC132008, MGC70799, OTTHUMP00000058954.

Background: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine, thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) , also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

Gen-ID: 1806

Pathways: Ribonucleoside Biosynthetic Process